Brief: Intellia Therapeutics Announces FDA Lift Of Clinical Hold On Magnitude Phase 3 Clinical Trial In Attr-Cm
02/03/2026 12:36
March 2 (Reuters) - Intellia Therapeutics Inc NTLA.O: INTELLIA THERAPEUTICS ANNOUNCES FDA LIFT OF CLINICAL HOLD ON MAGNITUDE PHASE 3 CLINICAL TRIAL IN ATTR-CM Source text: ID:nGNXbWWpCT Further company coverage: NTLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)